AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02660970
Drug: Iberogast
RxNorm normalized name: Iberogast Softgels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will have to take Iberogast drops
Trial: NCT04502901
Drug: KX0826
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigational AR antagonist
Trial: NCT00847249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single-dose.
Trial: NCT03128359
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04553458
Drug: Percutaneous ethanol injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection of HCC
Trial: NCT04553458
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment
Trial: NCT00915239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo once daily for 28 days
Trial: NCT00741455
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/m2/d IV on days -3 and -2
Trial: NCT00741455
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
Trial: NCT00098319
Drug: Folic acid (0.4mg vs. 4.0mg)
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03014375
Drug: BIA-5-453
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
Trial: NCT01968915
Drug: LCL161
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
Trial: NCT01914900
Drug: docetaxel, cisplatin, 5 fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03078322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Trial: NCT03284177
Drug: Calcium (13C)Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
Trial: NCT00003834
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003834
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03284177
Drug: Gastric acid inhibitors
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
Trial: NCT00242710
Drug: CE 0.45 mg/MPA 1.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Trial: NCT02763059
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
Trial: NCT02763059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group receives 1 hour before surgery placebo.
Trial: NCT02763059
Drug: Acetaminophen 1000 mg
RxNorm normalized name: acetaminophen 1000 MG
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
Trial: NCT00120926
Drug: Parenteral Nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01018030
Drug: FFNS 110 mcg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
Trial: NCT01018030
Drug: FFNS 110 mcg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Nasal Spray (AM) and Active Nasal Spray (PM)
Trial: NCT01018030
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
Trial: NCT03862586
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00890734
Drug: CYT003-QbG10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT00890734
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT00648336
Drug: Mercaptopurine 50 mg
RxNorm normalized name: mercaptopurine 50 MG
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg, single dose fasting
Trial: NCT00648336
Drug: Purinethol® Tablets 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, single dose fasting
Trial: NCT02460094
Drug: BIIB092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm Descriptions for dosing information.
Trial: NCT02460094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
Trial: NCT00373373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Placebo
Trial: NCT01792310
Drug: LAM561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of LAM561 may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances.
Trial: NCT03401372
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doxycycline 100mg twice daily
Trial: NCT03401372
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle
Trial: NCT01336543
Drug: Chemotherapy following concurrent Chemoradiotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. NSCLC (Non-Small Cell Lung Cancer)~2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~3. Radiation 59.4 Gy with 2 cycles of PE~4. (Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~5. (Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles
Trial: NCT00296036
Drug: urea/lactic acid-based topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT05414669
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was given orally for a total of 3 days, beginning a day before ESWL.
Trial: NCT00875966
Drug: Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
Trial: NCT02021864
Drug: prenatal multivitamin
RxNorm normalized name: Prenatal Multivitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
Trial: NCT00544154
Drug: CDP870
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03830463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT01836029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00362440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01070940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution IV priming dose + IV infusion for 1 hour
Trial: NCT00925977
Drug: Insulin NPH + Insulin Apidra: Active Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin NPH + Insulin Apidra: Active Comparator
Trial: NCT01526499
Drug: Docetaxel and Cyclophosphamide (TC)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
Trial: NCT01651767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=suspension, route=oral.
Trial: NCT02466906
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
Trial: NCT01066611
Drug: CAL-263
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL-263 10 mg or placebo once daily for 7 days
Trial: NCT01066611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL-263 10 mg or placebo once daily for 7 days
Trial: NCT04797923
Drug: 1. Treatment: IP chemotherapy + Systemic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Treatment: IP chemotherapy + Systemic chemotherapy Day1 + Day 8: IP Paclitaxel 40 mg/m2 every 3 weeks Day1: IV Oxaliplatin 100 mg/m2 every 3 weeks Day 1\~14: Capecitabine 1000 mg/m2 PO, BID every 3 weeks
Trial: NCT00429091
Drug: ABT-894
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
Trial: NCT00082628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to serostim® as subcutaneous injection.
Trial: NCT00082628
Drug: Serostim® 4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
Trial: NCT00082628
Drug: Serostim® 2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serostim® 2 mg as subcutaneous injection on alternate days.
Trial: NCT00429091
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take BID for up to four weeks
Trial: NCT01045460
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered at 2.5 g/m\^2.
Trial: NCT00011986
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03338816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (normal saline \[0.9% NaCl\]) by SC
Trial: NCT00988858
Drug: LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 milligram per square meter (mg/m\^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
Trial: NCT03773068
Drug: [13C715N]-BAY 181708 stable isotope label (SIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg \[13C715N\]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
Trial: NCT00004236
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00252421
Drug: Placebo ointment daily for 24 month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment applied daily for 24 mth
Trial: NCT00189098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03446872
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an active metabolite of folic acid
Trial: NCT01600885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
Trial: NCT03101930
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
Trial: NCT01021553
Drug: GSK557296
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg GSK557296
Trial: NCT01021553
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02180464
Drug: LAS41004
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00396344
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous stress dose of hydrocortisone
Trial: NCT00396344
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous pharmacologic hydrocortisone
Trial: NCT02319200
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets per day for 36 months
Trial: NCT02481154
Drug: AG881
RxNorm normalized name: Agenebrutinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Trial: NCT02073227
Drug: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Trial: NCT00456053
Drug: FG2216
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01306786
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d
Trial: NCT01306786
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
Trial: NCT02268149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00491751
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid 500 mg/day
Trial: NCT00491751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02455596
Drug: Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
Trial: NCT01888744
Drug: hP-hMG
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00785915
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single administration and once daily for 5 days
Trial: NCT00785915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single administration and once daily for 5 days
Trial: NCT02662894
Drug: Valsartan 160mg + Rosuvastatin 20mg
RxNorm normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet, oral, a day
Trial: NCT02662894
Drug: Valsartan 320mg + Rosuvastatin 20mg
RxNorm normalized name: valsartan 320 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet, oral, a day
Trial: NCT02538744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02662894
Drug: Diovan® 160mg + Crestor® 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
Trial: NCT02662894
Drug: Diovan® 320mg + Crestor® 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
Trial: NCT00472108
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01387217
Drug: GSK2018682
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2018682
Trial: NCT01387217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo
Trial: NCT00642356
Drug: Carbidopa/levodopa/entacapone
RxNorm normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
Trial: NCT00642356
Drug: Immediate release carbidopa/levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
Trial: NCT01472640
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 U sc QOD
Trial: NCT00686504
Drug: radioligand [11C] AZ12713580
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of iv administered 4 times per subject (3 times together with AZD2066)
Trial: NCT03169894
Drug: MDGN-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
Trial: NCT02160951
Drug: LGH447
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGH447, QD
Trial: NCT00972439
Drug: Oral Contraceptive: Ortho-Novum® 1/35
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02076659
Drug: F8IL10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Trial: NCT02076659
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent.
Trial: NCT03671252
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
Trial: NCT03671252
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
Trial: NCT01742663
Drug: Solaraze® (diclofenac sodium) Gel 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
Trial: NCT00150241
Drug: CP-526,555 (varenicline)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01657214
Drug: SAR125844
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Concentrate for solution~Route of administration: intravenous
Trial: NCT02094807
Drug: opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.